#healthcare #United Kingdom #Reacta #Allergy #Deeside

Reacta Healthcare Breaks New Ground in Multi-Allergen Production

In May 2025, Reacta Healthcare achieved a significant milestone as it commenced the production of pharmaceutical-grade challenge meals incorporating milk and egg. This development represents an expansion of their existing product range, which already included peanut challenge meals. The new offerings are set to play a crucial role in international clinical trials aimed at investigating innovative treatments for food allergies.

The Growing Need for Multi-Allergen Solutions

The relevance of addressing multiple food allergies, both in diagnosis and treatment, is becoming increasingly evident. Statistics indicate that among individuals with food allergies, approximately 46% of adults and 40% of children suffer from multiple allergies. This scenario underscores the necessity for healthcare professionals to adopt a more holistic approach to allergy management. Reacta's strategic introduction of egg and milk challenge meals alongside their existing peanut products reflects this urgent need, ensuring that the company meets the evolving demands of dietary research and clinical communities.

Standards of Quality and Safety

The new challenge meals are developed following stringent protocols at Reacta's cutting-edge manufacturing facility in Deeside, UK, which is licensed by the MHRA (Medicines and Healthcare products Regulatory Agency). The production methods adhere to the current Good Manufacturing Practices (cGMP), ensuring that products are standardized and safe for clinical use. Since 2017, these products have been successfully submitted for approval to various health regulatory agencies, including the FDA and EMA, further confirming their reliability.

Versatile Application in Clinical Trials

Reacta's challenge meals are suitable for all phases of clinical trials, utilized effectively in oral food challenge tests, double-blind, placebo-controlled trials. With the addition of egg and milk, the company is strategically positioned to supply a diverse array of challenge meals tailored to the needs of a growing clinical research community seeking antigen-agnostic indications for their therapies. Furthermore, plans to develop new challenge meals with additional allergens, including prototypes for hazelnut and cashew, are already under development.

Driving Innovation through Research and Development

Reacta Healthcare employs its extensive internal R&D capabilities to drive forward advancements in allergy research, diagnosis, and clinical practices. This focus on innovation not only addresses current gaps in allergy treatment but also sets new benchmarks for future developments within the industry. By maintaining rigorous research standards and prioritizing patient safety, Reacta stands as a key player in the supply of critical challenge meals essential for the global therapeutic landscape.

Conclusion

As the prevalence of food allergies continues to rise, Reacta Healthcare's commitment to developing multi-allergen solutions is both timely and necessary. Their focus on high-quality, standardized products positions them at the forefront of allergy research, providing much-needed support to healthcare professionals and patients alike. Through their unwavering dedication to innovation and patient safety, Reacta Healthcare is poised to make significant contributions to the understanding and treatment of food allergies globally.